ID

34480

Beschrijving

Periperal Blood Lymphocytes During Prostate RT; ODM derived from: https://clinicaltrials.gov/show/NCT01899391

Link

https://clinicaltrials.gov/show/NCT01899391

Trefwoorden

  1. 17-01-19 17-01-19 -
  2. 22-05-19 22-05-19 -
Houder van rechten

see on clinicaltrials.gov

Geüploaded op

17 januari 2019

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY-NC 3.0

Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Prostate Cancer NCT01899391

Eligibility Prostate Cancer NCT01899391

Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
intermediate-risk prostate cancer patients (t1/t2n0m0 with either gs < 7 and psa between 10-20 ng/ml or gs 7 and psa less than 20 ng/ml).
Beschrijving

ID.1

Datatype

boolean

planned for radical rt to the prostate with imrt planning (79gy/39fractions or 60 gy/20 fractions).
Beschrijving

ID.2

Datatype

boolean

no contraindications to diagnostic ct scanning.
Beschrijving

ID.3

Datatype

boolean

prostate volumes will be less than 80 cc to control the planning dose volume histogram (dvh) as much as possible in terms of rectal and bladder volumes.
Beschrijving

ID.4

Datatype

boolean

no known dna repair disorders (e.g. family history of at, brca1/2 or li fraumeni syndrome) or contraindications to radical pelvic rt.
Beschrijving

ID.5

Datatype

boolean

Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
inability to provide informed consent.
Beschrijving

ID.6

Datatype

boolean

patient having contraindications to diagnostic ct scan.
Beschrijving

ID.7

Datatype

boolean

patients who have unobtainable data regarding previous therapy and their clinical outcome.
Beschrijving

ID.8

Datatype

boolean

patients should not have any diagnostic x-rays or cat scans 2 weeks prior to their enrollment into the study.
Beschrijving

ID.9

Datatype

boolean

Similar models

Eligibility Prostate Cancer NCT01899391

Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
intermediate-risk prostate cancer patients (t1/t2n0m0 with either gs < 7 and psa between 10-20 ng/ml or gs 7 and psa less than 20 ng/ml).
boolean
ID.2
Item
planned for radical rt to the prostate with imrt planning (79gy/39fractions or 60 gy/20 fractions).
boolean
ID.3
Item
no contraindications to diagnostic ct scanning.
boolean
ID.4
Item
prostate volumes will be less than 80 cc to control the planning dose volume histogram (dvh) as much as possible in terms of rectal and bladder volumes.
boolean
ID.5
Item
no known dna repair disorders (e.g. family history of at, brca1/2 or li fraumeni syndrome) or contraindications to radical pelvic rt.
boolean
Item Group
C0680251 (UMLS CUI)
ID.6
Item
inability to provide informed consent.
boolean
ID.7
Item
patient having contraindications to diagnostic ct scan.
boolean
ID.8
Item
patients who have unobtainable data regarding previous therapy and their clinical outcome.
boolean
ID.9
Item
patients should not have any diagnostic x-rays or cat scans 2 weeks prior to their enrollment into the study.
boolean

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial